|
【结 构 式】 
|
【药物名称】NSC-638850, KW-2401, UCN-01 【化学名称】(8alpha,9beta,10beta,12alpha)-(+)-2,3,9,10,11,12-Hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-8,12-epoxy-1H,8H,2,7b,12a-trizadibenzo[a,g]cyclonona[cde]trinden-1-one 【CA登记号】112953-11-4 【 分 子 式 】C28H26N4O4 【 分 子 量 】482.54382 |
【开发单位】Kyowa Hakko (Originator), National Cancer Institute (Licensee) 【药理作用】Leukemia Therapy, Oncolytic Drugs, Solid Tumors Therapy, Apoptosis Inducers, CDK1 Inhibitors, CDK2 Inhibitors, CDK4 Inhibitors, CDK6 Inhibitors, Check Point Kinase 1 (Chk1) Inhibitors, Check Point Kinase 2 (Chk2) Inhibitors, Inhibitors of Signal Transduction Pathways, Phosphoinositide dependent Kinase (PDK) 1 Inhibitors, Protein Kinase C (PKC) Inhibitors |
合成路线1
The reaction of staurosporine (I) with benzyl chloroformate (II) by means of NaHCO3 in acetone gives the N-protected compound (II), which is oxidized with lead tetraacetate in HOAc to yield the hydroxy compound (III). Finally, this compound is deprotected by hydrogenation with H2 over Pd/C in DMF to obtain the target hydroxy staurosporine.
| 【1】 Murakata, C.; Sato, A.; Kasai, M.; Morimoto, M.; Akinaga, S. (Kyowa Hakko Kogyo Co., Ltd.); Staurosporin derivatives. EP 0383919; JP 2766360B2; WO 8907105 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 52822 | (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1~2,6~.0~7,28~.0~8,13~.0~15,19~.0~20,27~.0~21,26~]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one | C28H26N4O3 | 详情 | 详情 | |
| (II) | 56662 | benzyl (2S,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1~2,6~.0~7,28~.0~8,13~.0~15,19~.0~20,27~.0~21,26~]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl(methyl)carbamate | C36H32N4O5 | 详情 | 详情 | |
| (III) | 56663 | benzyl (2S,4R,6R)-18-hydroxy-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1~2,6~.0~7,28~.0~8,13~.0~15,19~.0~20,27~.0~21,26~]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl(methyl)carbamate | C36H32N4O6 | 详情 | 详情 |